Pacira BioSciences (NASDAQ:PCRX) CFO Shawn Cross Sells 7,714 Shares of Stock

Pacira BioSciences, Inc. (NASDAQ:PCRX) CFO Shawn Cross sold 7,714 shares of the business’s stock in a transaction on Monday, April 20th. The shares were sold at an average price of $25.14, for a total transaction of $193,929.96. Following the sale, the chief financial officer directly owned 105,341 shares in the company, valued at $2,648,272.74. The trade was a 6.82% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Shawn Cross also recently made the following trade(s):

• On Tuesday, April 21st, Shawn Cross sold 2,845 shares of Pacira BioSciences stock. The shares were sold at an average price of $25.01, for a total transaction of $71,153.45.
• On Wednesday, April 22nd, Shawn Cross sold 1,500 shares of Pacira BioSciences stock. The shares were sold at an average price of $25.01, for a total transaction of $37,515.00.

Pacira BioSciences Trading Up 1.0%

Shares of PCRX stock opened at $24.88 on Thursday. The company’s fifty day simple moving average is $22.96 and its two-hundred day simple moving average is $23.06. The company has a debt-to-equity ratio of 0.54, a current ratio of 4.54 and a quick ratio of 3.28. Pacira BioSciences, Inc. has a 1 year low of $18.80 and a 1 year high of $27.64. The stock has a market capitalization of $1.01 billion, a price-to-earnings ratio of 165.87 and a beta of 0.19.

Pacira BioSciences (NASDAQ:PCRX) last issued its earnings results on Thursday, February 26th. The company reported $0.57 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.85 by ($0.28). Pacira BioSciences had a net margin of 0.97% and a return on equity of 10.39%. The business had revenue of $196.87 million for the quarter, compared to the consensus estimate of $201.93 million. During the same period in the previous year, the firm earned $0.91 EPS. The company’s revenue was up 5.1% compared to the same quarter last year. As a group, analysts anticipate that Pacira BioSciences, Inc. will post 1.85 earnings per share for the current year.

Institutional Investors Weigh In On Pacira BioSciences

Several large investors have recently added to or reduced their stakes in the business. Doma Perpetual Capital Management LLC grew its stake in Pacira BioSciences by 49.7% in the 3rd quarter. Doma Perpetual Capital Management LLC now owns 2,701,324 shares of the company’s stock worth $69,613,000 after buying an additional 897,255 shares in the last quarter. Hussman Strategic Advisors Inc. purchased a new position in Pacira BioSciences in the 3rd quarter worth approximately $2,706,000. Impax Asset Management Group plc grew its stake in Pacira BioSciences by 27.7% in the 3rd quarter. Impax Asset Management Group plc now owns 600,027 shares of the company’s stock worth $15,463,000 after buying an additional 130,000 shares in the last quarter. Exchange Traded Concepts LLC purchased a new position in Pacira BioSciences in the 3rd quarter worth approximately $1,948,000. Finally, Assenagon Asset Management S.A. grew its stake in Pacira BioSciences by 87.3% in the 4th quarter. Assenagon Asset Management S.A. now owns 435,143 shares of the company’s stock worth $11,262,000 after buying an additional 202,773 shares in the last quarter. Institutional investors own 99.73% of the company’s stock.

Analyst Ratings Changes

PCRX has been the topic of a number of recent analyst reports. Zacks Research raised shares of Pacira BioSciences from a “strong sell” rating to a “hold” rating in a report on Tuesday, April 7th. Weiss Ratings reissued a “sell (d+)” rating on shares of Pacira BioSciences in a report on Monday, December 29th. HC Wainwright reissued a “buy” rating and issued a $38.00 price target on shares of Pacira BioSciences in a report on Friday, January 9th. Barclays lowered their price target on shares of Pacira BioSciences from $27.00 to $25.00 and set an “equal weight” rating on the stock in a report on Thursday, March 26th. Finally, Needham & Company LLC reissued a “buy” rating and issued a $30.00 price target on shares of Pacira BioSciences in a report on Friday, January 9th. Three investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $30.25.

About Pacira BioSciences

Pacira BioSciences, Inc is a specialty pharmaceutical company focused on developing and commercializing non-opioid, non-addictive pain management and regenerative health solutions. The company’s flagship product, EXPAREL, is a bupivacaine liposome injectable suspension designed to provide long-lasting postsurgical analgesia. EXPAREL is used by clinicians across a broad range of surgical procedures to reduce reliance on opioid medications and to help manage acute postoperative pain.

In addition to its marketed offering, Pacira maintains an active pipeline of investigational products aimed at addressing unmet needs in pain management and inflammation control.